natgillin/translations-raw huggingface dataset:
the aminocarbonyl optionally is substituted with one or two substituents independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkyloxyalkyl, carbocyclyl, heterocyclyl, alkylsulfonyl, and alkylsulfonylamino, wherein: the carbocyclyl and heterocyclyl optionally are substituted with one or two substituents independently selected from the group consisting of halo, alkyl, and oxo; 
svaki RI je neovisno odabran iz skupine koju sačinjavaju alkilkarbonil i aminokarbonil, pri čemu: minokarbonil je opcijski supstituiran supstituentom odabranim iz skupine koju sačinjavaju alkil, alkiloksialkil, alkilsulfonil i alkilsulfonilamino; svaki RJ je neovisno odabran iz skupine koju sačinjavaju alkilsulfonilamino, alkenilsulfonilamino, alkinilsulfonilamino i alkilsulfonilaminoimino, pri čemu:
A compound of formula (3) and its analogues substituted with methyl rather than chloromethyl and bromo, fluro or iodo in place of chloro. 
Spoj formule (3) Ca ČE, i njegovi analozi, naznačeni time što su supstituirani sa metilom prije nego sa klorometil, i bromo, fluro ili jodo umjesto kloro.
The composition for use of any of claims 1-5; wherein (a) the bacterial strain has a 16s rRNA sequence that is at least 95%, 96%, 97%, 98%, 99%, 99.5% or 99.9% identical to the 16s rRNA sequence of a bacterial strain of Blautia stercoris; or wherein (b) the bacterial strain has a 16s rRNA sequence that is at least 95%, 96%, 97%, 98%, 99%, 99.5% or 99.9% identical to SEQ ID NO:1 or 2; wherein according to (b), preferably the bacterial strain has a 16s rRNA sequence that is at least 95%, 96%, 97%, 98%, 99%, 99.5% or 99.9% identical to SEQ ID NO:2, or the bacterial strain has the 16s rRNA sequence represented by SEQ ID NO:2. 
Sastav za upotrebu prema bilo kojem od zahtjeva 1-5; pri čemu (a) i soj bakterije ima sekvenciju 16s rRNK koja je bar 95%, 96%, 97%, 98%, 99%, 99.5% ili 99.9% jednaku sa sekvencijom 16s rRNK soja bakterije Blautia stercoris; ili pri čemu (b) soj bakterije ima sekvenciju 16s rRNK koja je bar 95%, 96%, 97%, 98%, 99%, 99.5% ili 99.9% jednaka sa SEQ ID NO:1 ili 2; gdje prema (b), poželjno soj bakterije ima sekvenciju 16s rRNK koja je bar 95%, 96%, 97%, 98%, 99%, 99.5% ili 99.9% jednaka sa SEQ ID NO:2, ili soj bakterije ima sekvenciju 16s rRNK predstavljenu sa SEQ ID NO:2.
The compound of claim 1, wherein the moiety -Y1-R2 is selected from the group consisting of: 
Spoj prema zahtjevu 1, naznačen time da je skupina -Y'-R* odabrana iz skupine koju čine:
a LDPC decoder (r715-L1) configured to LDPC-decode the Layer 1 signaling data which the de-puncturing is performed on; and 
LDPC dekoder (1715-L1) konfiguriran za LDPC dekodiranje signalnog podatka razine 1 i sabijenog paritetnog bita; i
Fig. 3 shows a schematic for a variant of the circuit in fig. 2; 
SI. 3 prikazuje shemu za varijantu kruga sa slike 2
A process for preparing 14-hydroxycodeinone from a thebaine composition, characterized by process conditions which minimize or eliminate the production of 8,14-dihydroxy-7,8-dihydrocodeinone in the 14-hydroxycodeinone composition. The process of claim 1, wherein the thebaine composition is oxidized to form a 14-hydroxycodeinone composition under conditions which minimize or eliminate the production of 8,14-dihydroxy-7,8-dihydrocodeinone in the 14-hydroxycodeinone composition. 
Postupak za pripremu sastava oksikodon hidroklorida koji ima razinu 14-hidroksikodeinona manju od 25 ppm dovođenjem sastava oksikodonske baze koji ima spoj 8,14-dihidroksi-7,8-dihidrokodeinona u reakciju s klorovodičnom kiselinom, pri čemu je 8,14-dihidroksi-7,8-dihidrokodeinon preveden u 14-hidroksikodeinonom, i reduciranjem 14-hidroksikodeinona u oksikodon.
One of the fluids is used to operate a drilling tool 12 such as a water hammer while the other fluid is released into the hole upstream of the drilling tool 12 . 
Sustav (10) za bušenje tla prema jednom od zahtjeva 1 do 7 gdje je DTA čekić (12) vodeni čekić 1 gdje je radni fluid voda.
Thus, according to one embodiment, a process is provided wherein step a) is performed by firstly preparing an aqueous solution comprising a pharmaceutically effective amount of a buffering agent, wherein said buffering agent is succinate; then adding to the said solution of buffering agent a pharmaceutically acceptable amount of one or more excipients dissolved in water. 
Postupak pripreme smjese kaspofungina prema zahtjevu 8, naznačeno time da se korak a) provodi prvo pripremom vodene otopine koja obuhvaća farmaceutski djelotvornu količinu puferskog sredstva, pri čemu je pufersko sredstvo sukcinat; a zatim dodavanjem farmaceutski prihvatljive količine jedne ili više pomoćnih tvari otopljenih u vodi navedenoj otopini puferskog sredstva.
treating a compound of Formula (IV): where M+ is an alkali metal with an acid; followed by treatment with NH2OR" where R" is hydrogen, alkyl, or an oxygen protecting group; 
obradu spoja formule (IV): [image] s kiselinom, kod čega M+ jest alkalijski metal, čemu slijedi obrada s NH2OR", u čemu:
A developer supply container (1) according to any one of Claims 1 - 4, furthermore comprising a developer, wherein the developer in said developer supply container (1) has a fluidity energy of not less than 4.3x 10-4 kg.cm2/s2 and not more than 4.14x 10-3 kg.cm2/s2, and wherein said discharge opening (3a) has an area not more than 12.6 mm2. 
Spremnik za nadopunjavanje razvijača u skladu s patentnim zahtjevima 3 ili 4, naznačen time što dodatno sadrži Tazvijač, gdje razvijač u navedenom spremniku za nadopunjavanje razvijača (1) ima energiju fluidnosti od najmanje 4,3x10-4 kg.m'"/s i najviše 4,14x10-3 kg.m?/s', i gdje navedeni otvor za ispuštanje (3a) ima površinu od najviše 12,6 mm.
A prototype of the first object of the proposed invention is a method for development of oil pool (RU 2184842 C2, published on Jul. 
Prototip prvog ostvarenja predloženog izuma jest metoda za razvoj naftnog bazena (RU 2184842 C2, objavljeno 10. srpnja 2002.)
A dihydroazole compound of formula (I), or a pharmaceutically acceptable salt thereof: wherein: 
(a) spoj dihidroazola formule (1), ili njegovu veterinarski ili agrikulturno prihvatljivu sol:
In yet another aspect of the invention is a method of treating inflammatory conditions and immune or anaphylactic disorders associated with infiltration of leukocytes into inflamed tissues in a subject in need thereof which comprises administering to said subject a therapeutically effective amount of a compound of the invention. 
Upotreba spoja, ili njegove farmaceutski prihvatljive soli ili solvata, u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačena time što je navedeni spoj namijenjen proizvodnji medikamenta za liječenje upalnih stanja i imunosnih ili anafilaktičkih poremećaja povezanih s infiltracijom leukocita u upaljeno tkivo.
The polypeptide of item 2, comprising an amino acid sequence according to SEQ ID NO:1. 
Polipeptid iz patentnog zahtjeva 2, koji sadrži aminokiselinsku sekvencu u skladu sa SEK ID BR:1 ostaci 1-567.
Macitentan for use in the prevention or treatment of brain metastases according to claim 1, which use is in combination with both radiotherapy and a cytotoxic chemotherapy agent selected from paclitaxel, temozolomide and a mixture of paclitaxel and temozolomide. 
Macitentan za uporabu u prevenciji ili liječenju metastaza na mozgu u skladu s patentnim zahtjevom 1, naznačen time, da se koristi u kombinaciji s oboma, odnosno radioterapijom 1 citotoksičnim kemoterapijskim sredstvom odabranim od paklitaksela, temozolomida i smjese paklitaksela i temozolomida.
The method according to claim 21 wherein the inhibition of the binding of acetylcholine to a M3 muscarinic acetylcholine receptor is useful in the treatment of chronic obstructive lung disease, chronic bronchitis, asthma, chronic respiratory obstruction, pulmonary fibrosis, pulmonary emphysema, or allergic rhinitis. 
Spoj namijenjen upotrebi u skladu s patentnim zahtjevom 4, naznačen time se što bolest bira iz skupine koju čine kronična opstruktivna plućna bolest, kronični bronhitis, astma, kronična začepljenost dišnih puteva, plućna fibroza, plućni emfizem i alergijski rinitis.
In some embodiments, the polypeptide is fused to a second protein, preferably, the Fc portion of IgG. 
Tvar za uporabu u skladu s patentnim zahtjevom 4, pri čemu je drugi polipeptid Fc dio IgG.
The resulting crude residue is loaded on a pre-packed packed Isolute™ silica column and eluted with iso-hexane:ethyl acetate (1:8) to yield the titled compound as a white powder. 
Dobiveni sirov ostatak se stavi na predpakirani Isolute "" stupac silika gela i ispere se s izo-heksan:etil acetatom (1:8), čime se dobije naslovni spoj kao bijeli prah.
In some embodiments of these uses and all such uses described herein, the ROBO2 inhibitor blocks or reduces binding of ROBO2 to SLIT, to Nck, or to both. 
2. > Farmaceutski pripravak u skladu s patentnim zahtjevom 1, naznačen time što inhibitor ROBO2 sprječava ili smanjuje vezanje polipeptida ROBO2 na SLIT2, na Nck, ili na oba.
A composition for use according to Claim 1 or a composition as claimed in Claim 8, wherein the cyclodextrin is present at a concentration of 25% (w/v). 
Pripravak namijenjen upotrebi u skladu s patentnim zahtjevom 1 ili pripravak u skladu s patentnim zahtjevom 8, naznačen time što je ciklodekstrin prisutan u koncentraciji od 25% (tež./vol.).
The organic and aqueous layers were then separated and the organic layer combined with one ethyl acetate wash of the aqueous layer. 
Organski i vodeni slojevi se tada odvoje i organski sloj se kombinira s jednim vodenim slojem od ispiranja etilacetatom.
The ability of the GnRH antagonists to inhibit the major drug metabolizing enzymes in the human liver, namely, CYP2D6 and CYP3A4, can be evaluated in vitro according to a microtiter plate-based fluorimetric method described by Crespi et al. (Anal. 
Sposobnost antagonista GnRH da inhibiraju glavne enzime koji metaboliziraju lijekove u ljudskoj jetri, primjerice CYP2D6 i CYP3A4, može se provjeriti in vitro a fluorometrijskim postupkom na mikrotitarskim pločama, opisanim u Crespi i suradnici (Anal.
A facility according to claim 9 or 10, wherein the liquid outlet line of the condensation system is in fluid communication with the urea synthesis section. 
Pogon prema zahtjevu 9 ili 10, pri čemu je otvor za istjecanje tekućine povezan tekućinom s dijelom za sintezu uree.
Overall, these modifications, which are consistent with previous animal findings, characterize a profile of drug activity that improves awakening and cognitive activities. 
U cjelini, ove modifikacije, koje su konzistentne s prethodnim nalazima u životinja, karakteriziraju profil lijeka koji poboljšava budnost i kognitivne aktivnosti.
The floor panels as claimed in any one of the preceding claims, wherein the floor panels have a fold down locking system on the short edges (1c, 1d) with a flexible tongue (10) that allows locking with vertical folding. 
Podne ploče prema bilo kojem od prethodnih zahtjeva, naznačene time da podne ploče imaju preklopni sustav za zaključavanje na kratkim rubovima (lc, 1d) s fleksibilnim jezičeem (10) koji omogućuje zaključavanje vertikalnim preklapanjem.
For example, the combination therapy can include an anti-ActRIIB antibody of the present disclosure combined with at least one other muscle mass/strength increasing agent, for example, IGF-1, IGF-2 or variants of IGF-1 or IGF-2, an anti-myostatin antibody, a myostatin propeptide, a myostatin decoy protein that binds ActRIIB but does not activate it, a beta 2 agonist, a Ghrelin agonist, a SARM, GH agonists/mimetics or follistatin. 
Farmaceutski sastav prema zahtjevu 18 ili 19, naznačen time, da nadalje obuhvaća jedno ili više dodatnih djelotvornih sredstava. Farmaceutski sastav prema zahtjevu 20, naznačen time, da navedeno dodatno djelotvorno sredstvo je odabrano od sljedećih: IGF-1, IGF-2 ili varijante od IGF-1 ili IGF-2, protutijelo anti-miostatin, miostatin-propeptid, miostatin-decoy-protein koji veže ActRIIB, ali ga ne aktivira, beta 2-agonist, Ghrelin-agonist, SARM, GH-agonisti/mimetici i folistatin.
Injection device according to claim 3, wherein said second end is farther from said end of the medicine container than is said first end. 
Uređaj za ubrizgavanje prema patentnom zahtjevu 2, naznačen time što je navedeni drugi kraj (17) udaljeniji od navedenog kraja (4) spremnika za lijek (2) nego navedeni prvi kraj (15).
The blend was compressed into chewable tablets. A stable pharmaceutical composition in film coated tablet form comprising montelukast or a salt thereof and a pharmaceutically acceptable excipient selected from at least one of diluent, binder, disintegrant, wetting agent, lubricant, or glidant, provided that the pharmaceutically acceptable excipient is not microcrystalline cellulose, wherein the pharmaceutical composition is prepared by direct compression from a dry mix.. 
Stabilna farmaceutska kompozicija u obliku tablete obložene filmom, naznačena time što sadrži montelukast ili njegovu sol i farmaceutski prihvatljiv inertni punitelj izabran od najmanje jednog od razblaživača, vezivnog sredstva, sredstva za raspadanje, sredstva za vlaženje, lubrikanta ili klizajućeg sredstva, uz uvjet da farmaceutski prihvatljivi inertni punitelj nije mikrokristalna celuloza, pri čemu je farmaceutska kompozicija pripremljena direktnim prešanjem iz suhe mješavine.
expressing said first DNA sequence and said second DNA sequence so that said immunoglobulin heavy and light chains are produced as separate molecules in said transformed single host cell. 
eksprimiranje navedenog prvog DNA slijeda i navedenog drugog DNA slijed kako bi se proizvelo navedeni teški i laki lanac imunoglobulina kao zasebne molekule u navedenoj transformiranoj istoj stanici domaćinu.
The peptide according to claim 2, wherein said peptide is capable of stimulating CD4 or CD8 T cells. A fusion protein, consisting of the peptide according to any of Claims 1 to 3 fused to the N-terminal amino acids of the HLA-DR antigen-associated invariant chain (Ii). 
Peptid koji se sastoji od SEQ ID NO 3. Peptid u sklad s patentnim zahtjevom 1, pri čemu navedeni peptid može stimulirati CD8 ili CD4 stanica. Peptid u skladu s patentnim zahtjevom 1 ili 2, koji je fuzioniran u N-terminalne aminokiseline HLA-DR invarijantnog lanca vezanog za antigene (Ii).
A T cell genetically engineered to express a CAR, wherein the CAR comprises (a) an antigen binding domain that is an anti-CD19 scFv, (b) a costimulatory 4-1BB signaling region, and (c) a CD3 zeta signaling domain, for use in a method for treating cancer that comprises administering said T cell to a human diagnosed with cancer, wherein the anti-CD19 scFv comprises the amino acid sequence of SEQ ID NO:20 or the CD3 zeta signaling domain comprises the amino acid sequence of SEQ ID NO:24, and wherein said method generates a population of genetically engineered T cells that persists in the human for at least eight months, nine months, ten months, eleven months, twelve months, two years, or three years after administration, and wherein the human is resistant to at least one chemotherapeutic agent. 
T stanica koja je genetski konstruirana tako da eksprimira CAR, naznačena time što CAR sadrži (a) antigen vezujuću domenu koja je anti-CD19 scFv, (b) kostimulatorno signalno područje 4-IBB, i (c) signalnu domenu CD3 zeta za upotrebu u postupku za liječenje raka koji obuhvaća primjenu navedene T stanice kod čovjeka kojem je dijagnosticiran rak, pri čemu anti-CD19 scFv sadrži aminokiselinsku sekvencu prema SEQ ID NO:20 ili signalnu domenu CD3 zeta sadrži aminokiselinsku sekvencu prema SEQ ID NO:24, 1 pri čemu navedeni postupak stvara populaciju genetski konstruiranih T stanica koje perzistiraju u čovjeku najmanje osam mjeseci, devet mjeseci, deset mjeseci, jedanaest mjeseci, dvanaest mjeseci, dvije godine, ili tri godine nakon primjene, i pri čemu je čovjek otporan na liječenje najmanje jednim kemoterapijskim sredstvom.
%, based on the total weight of the coated micropellet. 
%, na osnovi ukupne mase obloženih mikropeleta.
A counter as claimed in claim 4, wherein said first engagement means comprise four arms each having a slot and a contact end. 
Brojač prema zahtjevu 4, naznačeno time da prvo sredstvo uključenja sadrži četiri ruke koja svaka ima utor i kontakt kraj.
There is thereafter undertaken step S 20 of entropy coding of the data of the aforementioned list Dm1, with the exception of the sign of the first non-zero data item a2 and of the sign of the second non-zero data item a3, which signs are hidden in the parity of the sum modulo 2N of the data. 
-a) - podatke o particijama (Bi) navedene kodirane slike, podaci o particiji (Bi) su koeficijenti izravne transformacije svake od particija, navedeni podaci navedene particije (Bi) sadrže znakove koeficijenata uz izuzetak znaka prvog koeficijenta koji nije nula za ovu particiju koji može biti sakriven;
Compound of formula II can be prepared by treatment of compound of formula Ia with Ac2O in a solvent such as CH2Cl2 containing pyridine and a catalyst such as dimethylaminopyridine (DMAP). 
Spoj formule II može se pripremiti tretmanom spoja formule la sa Ac2O u otapalu kao što je CH2CL koje 10 sadrži piridin i katalizator kao što je dimetilaminopiridin (DMAP).
The methods of preparing a polymer hydrogel of the present invention comprise the step of cross-linking an aqueous solution comprising a hydrophilic polymer with a polycarboxylic acid, thereby producing the polymer hydrogel. 
(b) zagrijavanje otopine radi uklanjanja vode i poprečnog povezivanja karboksimetilceluloze s limunskom kiselinom, pri čime se formira polimerni hidrogel; gdje navedeni polimerni hidrogel ima udio bubrenja u destiliranoj vodi od najmanje 50.
The process according to claim 41 wherein 3-phenylsulfanyl-1H-pyrrolo[3,2-b]pyridine-2-carboxylic acid amide is prepared. 
Postupak u skladu s patentnim zahtjevom 41, gdje se dobiva amid 3-fenilsulfanil-1/-pirolo[3,2-b |piridin-2- karboksilne kiseline.
The dried granules were screened through U.S. Standard Sieve No. 
Suhe granule se sortiraju sijanjem kroz U,S.
wherein C6-10 aryl, 2,3-dihydro-1 H -indolyl, and heteroaryl of Group b) are optionally independently substituted with one to two substitutents selected from the group consisting of chloro, fluoro, C14alkyl, C1-4alkoxy, and trifluoromethyl; and are substituted with one additional substituent selected from the group consisting of 
pri čemu su C6-10aril, 2,3-dihidro-1H-indolil, i heteroaril od Grupe b) opciono nezavisno supstituirani sa jednim do dva supstituenta izabrana iz grupe koju čine kloro, fluoro, C14alkil, C1-4alkoksi, i trifluorometil; i supstituirani su sa jednim dodatnim supstituentom izabranim iz grupe koju čine
The liquefied gas treatment system according to claim 1, further comprising a forcible vaporizer configured to forcibly vaporize the liquefied natural gas stored in the cargo tank and supply the vaporized liquefied natural gas to the compressor. 
Sustav za obradu ukapljenog plina u skladu s patentnim zahtjevom 1, naznačen time što dodatno sadrži prisilni isparivač, podešen za prisilno isparavanje LNG spremljenog u spremniku za teret i slanje prisilno isparenog LNG u kompresor.
A process for the preparation of compounds of formula (VI) which comprises reducing a compound of formula (V) to form a compound of formula (VI): 
Postupak za dobivanje spojeva formule (VI) naznačen time da sadrži redukciju spoja formule (V) koja tvori spoj formule (VI):
When applied, the moisture and air permeable lacquer did not burn or cause irritation on the adjacent skin or the periungual bed. 
Kod primjene, vlažni i za zrak propusni lak nije žario ili uzrokovao iritaciju okolne kože ili periungualnog ležišta.
The antibody or functional protein according to Claim 5, characterized in that said antibody or functional protein has an IC50 less than 1µM, preferably less than 500nM and more preferably less than 200nM as measured in BMP2-induced mineralization assay in MC3T3 cells in the presence of sclerostin 
Protutijelo ili njegov dio koji veže antigen prema zahtjevu 5, naznačeno time da navedeno protutijelo ili njegov dio koji veže antigen ima vrijednost ICs, manju od 1 uM, poželjno manju od 500 nM i poželjnije manju od 200 nM kako je mjereno sa BMP2-induciranim testom mineralizacije kod MC3T3 stanica u prisutnosti sklerostina.
The diethyl esters all show good cytotoxicity in HL-60 cells, and many show significant inhibition of GSTπ as measured in the immunoprecipitation assay. 
Svi dietil esteri pokazuju dobar citotoksicitet u HL-60 stanicama, a mnogi pokazuju značajnu inhibiciju GSTa kako je izmjereno u imunoprecipitacijskim pokusima.
forming a first composition comprising the trans-(-)-A9-tetrahydrocannabinol from step (b), trans-(+)-A9-tetrahydrocannabinol, and a non-polar organic solvent. 
(c) formiranje prvog sastava koji sadrži trans-(-)-A'-tetrahidrokanabinol iz koraka (b), trans-(+)-A'- tetrahidrokanabinol, te nepolarno organsko otapalo. .
Preferred embodiments are subject of the dependent claims. In particular, the gist of the invention is the following: A method of delivering content via a network from a server to a client having a first network interface comprises: the client providing a request for content to the server via a first vector wherein the first vector is associated to the first network interface; the server receiving context information about the context of the client; the server separating the content to be delivered to the client in accordance with the request into small content and large content; the server defining a transfer procedure for the large content based on the context information; the server providing a first response to the client via the first vector wherein the first response comprises the small content and information about the transfer procedure of the large content; and the client receiving the large content in accordance with the information about the transfer procedure of the large content. 
Postupak slanja sadržaja preko mreže iz servera prema klijentu koji ima prvo mrežno sučelje, naznačen time što se sastoji u tome da klijent šalje upit za sadržaj u server preko prvog vektora, gdje se prvi vektor odnosi na put unutar specifične mrežne tehnologije i povezan je s prvim mrežnim sučeljem; server prima kontekstne informacije o kontekstu klijenta, gdje kontekstne informacije sadrže informacije o klijentovom uređaju, njegovom lokalnom okolišu koji se stalno može mijenjati dok je klijent u pokretu i njegovim mrežnim vezama ili mrežnim sučeljima i njihovoj dostupnosti; server razdvaja sadržaj koji treba poslati klijentu u skladu s upitom na mali sadržaj i veliki sadržaj; server određuje proceduru prijenosa velikog sadržaja na osnovi kontekstnih informacija; server šalje prvi odgovor klijentu preko prvog vektora, gdje prvi odgovor sadrži mali sadržaj i informacije o proceduri prijenosa velikog sadržaja; i klijent prima veliki sadržaj u skladu s informacijama o proceduri prijenosa velikog sadržaja.
The composition according to claim 3, wherein the sugar is selected from the group consisting of D-mannitol, erythritol, isomalt and trehalose. 
Uporaba prema zahtjevu 7, naznačena time da je šećer odabran iz skupine koja se sastoji od D-manitola, eritritola, izomalta i trehaloze.
ivb) adding an amine group to the 6 position of the pyridyl moiety to produce compound 6a, wherein the amination reaction is carried out in the presence of a sulfonyl compound, wherein, R is H, C1-6 aliphatic, aryl, aralkyl, heteroaryl, cycloalkyl, or heterocycloalkyl; and 
ivb) dodavanje amino grupe na položaj 6 piridil grupe da se proizvede spoj 6a, [image] pri čemu se reakcija aminacije izvodi u prisustvu sulfonil spoja, pri čemu, R je H, C1-6 alifat, aril, aralkil, heteroaril, cikloalkil ili heterocikloalkil; i
The polymer moiety of the polymer conjugate of the invention is conjugated to the HMGB1 polypeptide or polypeptide variant by a covalent chemical bond in order to provide a stable conjugate. 
Polimerni konjugat iz bilo kojeg od zahtjeva 1 do 4, naznačen time, što je polimerna komponenta kovalentno vezana za HMGB1 Box-A polipeptid, HMGB1 Box-A polipeptidnu varijantu ili njihov biološki aktivni fragment.